Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation

PURPOSE AND DESIGN: Mechanism(s) by which the multi-kinase inhibitor sorafenib and the histone deacetylase inhibitor vorinostat interact to kill hepatic, renal and pancreatic adenocarcinoma cells have been defined. RESULTS: Low doses of sorafenib and vorinostat interacted in vitro in a synergistic f...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Zhang, Guo, Park, Margaret A., Mitchell, Clint, Hamed, Hossein, Rahmani, Mohammed, Martin, Aditi Pandya, Curiel, David T., Yacoub, Adly, Graf, Martin, Lee, Ray, Roberts, John D., Fisher, Paul B., Grant, Steven, Dent, Paul
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2561272/
https://ncbi.nlm.nih.gov/pubmed/18765530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0469
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky